Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Zhejiang Shapuaisi Pharmaceutical Co's Liquidation Value for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shapuaisi Pharmaceutical Co Total Current Assets Related Terms
Zhejiang Shapuaisi Pharmaceutical Co Total Current Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shapuaisi Pharmaceutical Co Total Current Assets Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of ¥283.7 Mil mean?
Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) has a Total Current Assets of ¥283.7 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Zhejiang Shapuaisi Pharmaceutical Co and its competitors.
Is Zhejiang Shapuaisi Pharmaceutical Co's Total Current Assets too high?
Zhejiang Shapuaisi Pharmaceutical Co's current Total Current Assets is ¥283.7 Mil. Overall, Zhejiang Shapuaisi Pharmaceutical Co has a GF Score™ of 37/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shapuaisi Pharmaceutical Co's Total Current Assets compare to ZTS and UTHR?
Zhejiang Shapuaisi Pharmaceutical Co's Total Current Assets of ¥283.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Zhejiang Shapuaisi Pharmaceutical Co and its competitors. Zhejiang Shapuaisi Pharmaceutical Co's current Total Current Assets is ¥283.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shapuaisi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥8.92, compared to a current price of ¥4.74 — trading 46.9% below its estimated fair value. The current Total Current Assets is ¥283.7 Mil. Zhejiang Shapuaisi Pharmaceutical Co's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168), the current Total Current Assets is ¥283.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.74 is trading 46.9% below its estimated GF Value™ of ¥8.92.
GuruFocus considers Zhejiang Shapuaisi Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:603168:
Total Current Assets: ¥283.7 Mil
GF Value™: ¥8.92 vs. price of ¥4.74 (46.9% below fair value)
No single metric tells the full story. See the SHSE:603168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Shapuaisi Pharmaceutical Co Business Description
Zhejiang Shapuaisi Pharmaceutical Co Ltd is a China based pharmaceutical company. It is engaged in drug research and development, production and operation. The product portfolio of the company includes oral solutions, eye drops, tablets, hard capsules, suppositories, granules, raw materials dosage forms such as medicines, rinsing agent and mixture, and others. The company operates pharmaceutical manufacturing companies, pharmaceutical sales company, pharmaceutical retail company and pharmaceutical research institute. The products offered by the company are sold in China and are also exported to the other countries.
37GF Score
Get the complete analysis for SHSE:603168
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603168 has been successfully added to your 
